The Supreme Court has questioned the Centre regarding the significant disparity between the Maximum Retail Price (MRP) of medicines and their price to retailers, suggesting the entire system might be favouring manufacturers. The court also expressed concerns about the National Pharmaceutical Pricing Authority (NPPA). The Supreme Court has critically questioned the Centre regarding the substantial disparity between medicine MRPs and retailer prices, raising concerns about pharmaceutical manufacturer favouritism and the National Pharmaceutical.